Philip Quinlan
Philip Quinlan
Verified email at
Cited by
Cited by
A Pin1/mutant p53 axis promotes aggressiveness in breast cancer
JE Girardini, M Napoli, S Piazza, A Rustighi, C Marotta, E Radaelli, ...
Cancer cell 20 (1), 79-91, 2011
Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS)
AM Thompson, LB Jordan, P Quinlan, E Anderson, A Skene, JA Dewar, ...
Breast cancer research 12 (6), R92, 2010
Histological evaluation of AMPK signalling in primary breast cancer
SM Hadad, L Baker, PR Quinlan, KE Robertson, SE Bray, G Thomson, ...
BMC cancer 9 (1), 307, 2009
CYP2D6 Genotype and Adjuvant Tamoxifen: Meta‐Analysis of Heterogeneous Study Populations
MA Province, MP Goetz, H Brauch, DA Flockhart, JM Hebert, R Whaley, ...
Clinical Pharmacology & Therapeutics 95 (2), 216-227, 2014
Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies
E Amir, M Clemons, CA Purdie, N Miller, P Quinlan, W Geddie, ...
Cancer treatment reviews 38 (6), 708-714, 2012
Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study
CA Purdie, P Quinlan, LB Jordan, A Ashfield, S Ogston, JA Dewar, ...
British journal of cancer 110 (3), 565-572, 2014
A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences
AM Shaaban, GR Ball, RA Brannan, G Cserni, A Di Benedetto, J Dent, ...
Breast cancer research and treatment 133 (3), 949-958, 2012
Therapeutic targeting of integrin αvβ6 in breast cancer
KM Moore, GJ Thomas, SW Duffy, J Warwick, R Gabe, P Chou, IO Ellis, ...
JNCI: Journal of the National Cancer Institute 106 (8), 2014
p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients
JC Bourdon, MP Khoury, A Diot, L Baker, K Fernandes, M Aoubala, ...
Breast Cancer Research 13 (1), R7, 2011
ERβ1 represses basal-like breast cancer epithelial to mesenchymal transition by destabilizing EGFR
C Thomas, G Rajapaksa, F Nikolos, R Hao, A Katchy, CW McCollum, ...
Breast cancer research 14 (6), 1-15, 2012
Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy
AM Thompson, A Johnson, P Quinlan, G Hillman, M Fontecha, SE Bray, ...
Breast cancer research and treatment 125 (1), 279-287, 2011
Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53mutation and poor clinical outcome
SI King, CA Purdie, SE Bray, PR Quinlan, LB Jordan, AM Thompson, ...
Breast cancer research 14 (2), R40, 2012
High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer
PG Roy, N Pratt, CA Purdie, L Baker, A Ashfield, P Quinlan, ...
International journal of cancer 127 (2), 355-360, 2010
Endoglin expression in breast tumor cells suppresses invasion and metastasis and correlates with improved clinical outcome
LA Henry, DA Johnson, D Sarrió, S Lee, PR Quinlan, T Crook, ...
Oncogene 30 (9), 1046-1058, 2011
p53 mutation, deprivation and poor prognosis in primary breast cancer
L Baker, PR Quinlan, N Patten, A Ashfield, LJ Birse-Stewart-Bell, ...
British journal of cancer 102 (4), 719-726, 2010
Tissue confirmation of disease recurrence in patients with breast cancer: Pooled analysis of two large prospective studies.
E Amir, M Clemons, OC Freedman, N Miller, RE Coleman, C Purdie, ...
Journal of Clinical Oncology 28 (15_suppl), 1007-1007, 2010
The prolyl 3-hydroxylases P3H2 and P3H3 are novel targets for epigenetic silencing in breast cancer
R Shah, P Smith, C Purdie, P Quinlan, L Baker, P Aman, AM Thompson, ...
British journal of cancer 100 (10), 1687-1696, 2009
Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study
CA Purdie, L Baker, A Ashfield, S Chatterjee, LB Jordan, P Quinlan, ...
British journal of cancer 103 (4), 475-481, 2010
High frequency of complex TP53 mutations in CNS metastases from breast cancer
CL Nigro, D Vivenza, M Monteverde, L Lattanzio, O Gojis, O Garrone, ...
British journal of cancer 106 (2), 397-404, 2012
NT5E CpG island methylation is a favourable breast cancer biomarker
CL Nigro, M Monteverde, S Lee, L Lattanzio, D Vivenza, A Comino, ...
British journal of cancer 107 (1), 75-83, 2012
The system can't perform the operation now. Try again later.
Articles 1–20